NCT05614310 · RECRUITING
Detecting Early Alzheimer's Using MR
This trial is testing whether a special type of MRI scan called glucoCEST can detect changes in brain glucose metabolism that show up early in Alzheimer's disease. Right now, that kind of brain imaging requires a PET scan with a radioactive tracer. The researchers want to know if MRI alone can do the same job. The phase is unspecified, suggesting this is early-stage feasibility or observational work, not a drug test.
Eligibility criteria
Inclusion Criteria: Development phase: Controls (development group) must: * be > 18 years * consent to the study * not report problems with memory. Clinical phase Patients must: * be ≥ 65 years, * able to provide informed consent to the study * have been clinically diagnosed with AD by the mental health team. Controls must: * be ≥ 65 years * able to provide consent to the study * have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE) * not report problems with memory. Exclusion Criteria: Subjects will not be considered if they: * have a history of diabetes, * have history of a major stroke (mini-stroke/Transient Ischaemic Attacks or lacunar stroke are acceptable), * have contra-indications to MRI scanning such as implantable cardiac devices * have family history in AD, to exclude possible gene mutations associated with AD * have advanced AD who lack the capacity to consent. * Are pregnant (for developmental phase) * are unable to read or speak English
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-03-30